Abstract 236P
Background
This study aimed to determine the changes to body composition and the risk of adverse effects associated with chemotherapy in patients with advanced urothelial carcinoma (UC). The study also investigated whether bioimpedance analysis (BIA) is an effective method for diagnosing body composition.
Methods
We prospectively evaluated the body composition of 60 patients with locoregional muscle invasive (≥ T2 and N0-2M0) or metastatic UC between April 2021 and June 2023 at the Department of Urology, Juntendo Nerima Hospital, Tokyo, Japan. Body composition was evaluated using multifrequency BIA at baseline and during chemotherapy. The change in body composition was compared between before and during chemotherapy, and the incidence of adverse events was also determined.
Results
Twelve of the 60 patients enrolled in the study failed to complete their planned chemotherapy regimens or the chemotherapy regimen was discontinued or changed due to adverse events or problems related to underlying cancer. The patients who discontinued their treatment were significantly older and had a low muscle mass and a low skeletal muscle index. To assess the time-course changes in the body composition of the 41 patients who underwent chemotherapy, BIA was performed before each cycle. Chemotherapy-associated changes included a reduction in body weight 1.3% (±0.6%) and a decrease in fat mass 6.4% (±3.4%), while muscle mass did not change 0 .0% (±0.8%) between each cycle. Patients, aged 75 years or younger, had a more significant loss of muscle mass than older patients with a low muscle mass at baseline. (2.3% ± 1.0 % vs -1.4% ±1.1%, p=0.033).
Conclusions
BIA may be used as a method of nutrition and muscle assessment for pretreatment risk stratification of patients with advanced UC treated with chemotherapy. Moreover, our findings suggest that elderly patients with a low muscle mass may have trouble completing their chemotherapy course. Furthermore, chemotherapy is associated with changes in body composition which may lead to a loss of muscle mass in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract